Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome.
In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.
Abeyagunawardena
A S
AS
Nephrourology Unit, Institute of Child Health, London, UK.
Goldblatt
D
D
Andrews
N
N
Trompeter
R S
RS
D000553:Ambulatory Care; D016207:Cytokines / Q000009:adverse effects / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008585:Meningitis, Meningococcal / Q000276:immunology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000009:adverse effects* / Q000627:therapeutic use*; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology*; D012008:Recurrence; D012307:Risk Factors; D014611:Vaccination / Q000009:adverse effects*
D016207:Cytokines; D022401:Meningococcal Vaccines; C410218:serogroup C meningococcal conjugate vaccine